Study halted: Long-Term safety of rare blood disorder drug under scrutiny
Disease control
Terminated
This study aimed to check the long-term safety and side effects of an investigational drug called SAR445088 in adults with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. It planned to follow a small group of participants for up to two y…
Phase: PHASE1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC